BIKTARVY 50Mg-200Mg-25Mg Tablet

DRUG5 trials

Sponsors

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba, University of Miami, Chelsea and Westminster NHS Foundation Trust, Servicios de Salud IPS Suramericana S.A.S

Conditions

Drug UseHIV InfectionsHIV TreatmentHIV-1-infectionHarm ReductionHuman Immunodeficiency Virus

Phase 1

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

CompletedNCT04950530

Chelsea and Westminster NHS Foundation TrustHIV-1-infection

Start: 2022-12-22End: 2024-02-29Updated: 2024-12-10

Phase 4

Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'BaHIV Infections

Start: 2020-08-17End: 2022-06-30Target: 27Updated: 2022-06-10

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

CompletedNCT04650269

University of MiamiDrug Use, Harm Reduction, HIV Infections

Start: 2021-03-04End: 2023-12-31Updated: 2025-01-08

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

TerminatedNCT04944654

Chelsea and Westminster NHS Foundation TrustHuman Immunodeficiency Virus

Start: 2023-01-07End: 2023-05-11Updated: 2024-05-13

Unknown Phase

Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia

CompletedNCT06829082

Servicios de Salud IPS Suramericana S.A.SHIV Treatment

Start: 2024-11-15End: 2025-01-17Updated: 2025-02-17